|
|
Article: Collaboration for aspirin-resistance testing announced.
- Article from:
- Science Letter
- Article date:
- December 7, 2004
CopyrightCOPYRIGHT 2004 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
2004 DEC 7 - (NewsRx.com & NewsRx.net) -- Corgenix Medical Corp. (CONX) and AspirinWorks, a division of Creative Clinical Concepts, Inc., (CCC), both headquartered in Denver, Colorado, announced that together they have entered into a license agreement with McMaster University (McMaster), Hamilton, Ontario, providing Corgenix and CCC exclusive rights to the propriety technology owned by McMaster for the development, manufacturing, and marketing of innovative diagnostic tests specific to the pathway by which aspirin acts on platelets.
This technology has demonstrated the ability to assess an individual's relative risk for heart attack by measuring the person's ...
Related newspaper, magazine, and journal articles:
|
|
Article: McMaster University leads trial in the prevention ...
Cardiovascular Week;
April 28, 2003 ;
682 words
... ... professor of medicine at McMaster University in Hamilton, Ontario, Canada ... compliance," Connolly added. "Aspirin, the only standard alternative ... with AF. Clopidogrel plus aspirin, which inhibits platelet ... ACTIVE W), and compared with aspirin alone in a second trial ...
|
|